KUALA LUMPUR (Feb 16): Biotechnology company Moderna Inc is expanding its commercial network across Asia with the addition of four new subsidiaries in Malaysia, Taiwan, Singapore, and Hong Kong.
In a statement Wednesday (Feb 16), the firm said the expansion comes as it scales up the manufacturing and distribution of its Covid-19 vaccine and future mRNA vaccines and therapeutics.
The company said the Asia-Pacific region represents an integral part of Moderna's business, with established subsidiaries in Japan, South Korea, and Australia.
Moderna chief executive officer Stephane Bancel said 2021 was a year of impact for the company.
"With the addition of four subsidiaries in Asia, we look forward to new opportunities to leverage our mRNA platform to help solve health challenges, including those with a high burden of disease in the Asia-Pacific region," he said.
Bancel said Asia bears the highest burden of infectious diseases, and the burden of non-communicable diseases is increasing as the population ages.
He said Moderna's growing portfolio in prophylactic vaccines, cardiovascular diseases, oncology, and rare diseases presents an opportunity to use mRNA technology to maximise the potential impact the company can have on human health in the region.
Bancel said Moderna currently has a presence in 12 markets globally.
He said regulators have approved Moderna's Covid-19 vaccine in more than 70 markets, including Canada, Japan, the European Union, the UK, and Israel.
In 2021, 807 million doses of Moderna's Covid-19 vaccine were shipped globally, with approximately 25% of those doses shipped to low- and middle-income markets, he said.